Cellectis(US:CLLS)2020-09-11 14:54Company Overview and Pipeline - Cellectis is committed to developing allogeneic CAR T-cells, with over 20 years of expertise in gene editing and 8 years in allogeneic CAR-T manufacturing[2] - The company has 6 ongoing clinical trials as of 2020, with 3 Cellectis-sponsored and 3 partnered[2] - Cellectis' pipeline includes innovative cancer therapies for unmet needs, such as UCART123 for Acute Myeloid Leukemia, UCART22 for Acute Lymphoblastic Leukemia, and UCARTCS1 for Multiple Myeloma[8] - Cellectis is constructing two in-house manufacturing plants, one in Paris, France, for raw material supply, and another in Raleigh, North Carolina, for GMP commercial-scale UCART manufacturing[29] Partnerships and Licensing - Cellectis has partnerships with industry leaders, with up to $3.2 billion in potential milestone payments plus royalties[5] - The company granted Servier an exclusive worldwide license to develop and commercialize all next-generation gene-edited allogeneic CAR T-cell products targeting CD19, including rights to ALLO-501[11] - Cellectis granted Allogene an exclusive license to 15 allogeneic CAR T-Cell targets including UCARTBCMA / ALLO-715, with up to $2.8 billion in development & sales milestones plus high single-digit royalties on sales[5] Clinical Trial Data and Efficacy - In a Phase 1 dose escalation study of ALLO-501 in R/R Non-Hodgkin Lymphoma, the overall response rate was 63%, and the complete response rate was 37%[11] - In a Phase 1 dose escalation study of UCART19 in R/R ALL, the CR/CRi rate with optimal lymphodepletion was 82%[13] - CD123 is expressed in >90% on malignant cells in AML[14] - CD22 is expressed in >95% B-ALL cells[16]